Case series shows complete resolution of paronychia in children receiving MEK inhibitors, suggesting a safe intervention.
Paronychia is a frequent cutaneous adverse event associated with MEK inhibitor therapy and may significantly impair quality of life and compromise treatment adherence. Treatment is usually medical, with poor and unsustained results. We retrospectively evaluated the safety and efficacy of CO 2 laser matrixectomy in children at a tertiary center between 2016 and 2026. Five patients with prolonged symptoms despite multiple conservative treatments were identified. Complete resolution was achieved in all patients, with no procedure‐related complications. MEK inhibitor therapy was continued without recurrence of paronychia. Outcomes remained favorable during a mean follow‐up of 4 years.
No takes yet. Share an insight, caveat, or question.
Friedland et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: